Literature DB >> 26703170

Hepatosteatosis and carotid intima-media thickness in patients with myocardial infarction.

Hasan Öztürk1,2, Hasan Ali Gümrükçüoğlu3, Mehmet Yaman4, Aytaç Akyol5, Şenay Öztürk5, Serkan Akdağ5, Hakkı Şimşek5, Musa Şahin5, Zeki Yüksel Günaydın6.   

Abstract

PURPOSE: The aim of the study was to determine the involvement of non-alcoholic fatty liver disease (NAFLD) in myocardial infarction patients and its relation with carotid intima-media thickness (CIMT).
METHODS: This study consisted of 224 patients divided into three groups: those with myocardial infarction (MI), stable coronary artery disease (CAD), and normal coronary artery. Measurement of CIMT and abdominal ultrasonography for hepatosteatosis was performed in all participants.
RESULTS: NAFLD was significantly more frequent among MI patients compared to the other groups. There was a significant difference between CAD and the presence of NAFLD (p < 0.05). Also, we found significant correlations between the severity of CAD and hepatosteatosis grade (r = 0.648, p < 0.001), CAD and CIMT (r = 0.594, p < 0.001), and NAFLD and CIMT (r = 0.233, p = 0.005). NAFLD was also significantly correlated with the severity of CAD (r = 0.607, p < 0.001), and the grade of NAFLD significantly correlated with CIMT (r = 0.606, p < 0.001).
CONCLUSION: Patients with more severe CAD were more likely to have NAFLD. In addition, hepatosteatosis may be associated with coronary plaque instability and high fatty volume. Patients with NAFLD should be screened regularly for other cardiovascular risk factors, and the presence of fatty liver may help better classify these patients.

Entities:  

Keywords:  Carotid intima-media thickness; Hepatosteatosis; Myocardial infarct

Mesh:

Year:  2015        PMID: 26703170     DOI: 10.1007/s10396-015-0649-x

Source DB:  PubMed          Journal:  J Med Ultrason (2001)        ISSN: 1346-4523            Impact factor:   1.314


  28 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease.

Authors:  G Targher; L Bertolini; R Padovani; F Poli; L Scala; R Tessari; L Zenari; G Falezza
Journal:  Diabet Med       Date:  2006-04       Impact factor: 4.359

3.  Sonographic fatty liver, overweight and ischemic heart disease.

Authors:  Yu-Cheng Lin; Huey-Ming Lo; Jong-Dar Chen
Journal:  World J Gastroenterol       Date:  2005-08-21       Impact factor: 5.742

4.  Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects.

Authors:  Giovanni Musso; Roberto Gambino; Simona Bo; Barbara Uberti; Giampaolo Biroli; Gianfranco Pagano; Maurizio Cassader
Journal:  Diabetes Care       Date:  2007-12-04       Impact factor: 19.112

5.  Universal definition of myocardial infarction.

Authors:  Kristian Thygesen; Joseph S Alpert; Harvey D White
Journal:  Eur Heart J       Date:  2007-10       Impact factor: 29.983

6.  Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.

Authors:  Giovanni Targher; Lorenzo Bertolini; Felice Poli; Stefano Rodella; Luca Scala; Roberto Tessari; Luciano Zenari; Giancarlo Falezza
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

Review 7.  Nonalcoholic fatty liver disease and the metabolic syndrome.

Authors:  Giulio Marchesini; Rebecca Marzocchi; Federica Agostini; Elisabetta Bugianesi
Journal:  Curr Opin Lipidol       Date:  2005-08       Impact factor: 4.776

8.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

9.  Fatty infiltration of the liver: analysis of prevalence, radiological and clinical features and influence on patient management.

Authors:  A Y el-Hassan; E M Ibrahim; F A al-Mulhim; A A Nabhan; M Y Chammas
Journal:  Br J Radiol       Date:  1992-09       Impact factor: 3.039

10.  Association between nonalcoholic fatty liver disease and coronary artery disease.

Authors:  Uğur Arslan; Sedat Türkoğlu; Serhat Balcioğlu; Yusuf Tavil; Tarkan Karakan; Atiye Cengel
Journal:  Coron Artery Dis       Date:  2007-09       Impact factor: 1.439

View more
  4 in total

1.  Relationships between severity of steatosis with glycemic control and carotid intima-media thickness among diabetic patients with ischemic heart disease.

Authors:  Nurazam Omar; Marymol Koshy; Mohammad Hanafiah; Sharifah Faradilla Wan Muhammad Hatta; Fatimah Zaherah Mohd Shah; Bushra Johari; Idris Zamhuri; Sazzli Shahlan Kasim; Thuhairah Abdul Rahman; Rohana Abdul Ghani
Journal:  J Res Med Sci       Date:  2020-06-30       Impact factor: 1.852

2.  The Correlation and Risk Factors between Carotid Intima-Media Thickening and Alcoholic Liver Disease Coupled with Helicobacter pylori Infection.

Authors:  Qu Bao-Ge; Wang Hui; Jia Yi-Guo; Su Ji-Liang; Wang Zhong-Dong; Wang Ya-Fei; Han Xing-Hai; Liu Yuan-Xun; Pan Jin-Dun; Ren Guang-Ying
Journal:  Sci Rep       Date:  2017-02-21       Impact factor: 4.379

3.  Nonalcoholic Fatty Liver Disease-Associated Liver Fibrosis Is Linked with the Severity of Coronary Artery Disease Mediated by Systemic Inflammation.

Authors:  Ling-Zi Chen; Xu-Bin Jing; Chao-Fen Wu; Yi-Cheng Zeng; Yan-Chun Xie; Mu-Qing Wang; Wen-Xia Chen; Xi Hu; Yan-Na Zhou; Xian-Bin Cai
Journal:  Dis Markers       Date:  2021-12-28       Impact factor: 3.434

4.  Relationship between AGT rs2493132 polymorphism and the risk of coronary artery disease in patients with NAFLD in the Chinese Han population.

Authors:  Mengzhen Dong; Shousheng Liu; Mengke Wang; Yifen Wang; Yongning Xin; Shiying Xuan
Journal:  J Int Med Res       Date:  2021-07       Impact factor: 1.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.